06660 艾美疫苗
AIM VACCINE
AIM VACCINE
| Listing Date | 2022/10/06 |
| Listing Price | 16.160 |
Subscription Result
- Subscription Rate3.15x
- Guarantee One Lot Size5 lot
- One Lot Success Rate60.02%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
AIM Vaccine Co. is a major vaccine company in China. It is the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), accounting for a 7.4% market share. In terms of 2021 sales revenue, it accounted for a 2.1% market share in the PRC.
The Group has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies.
The Group currently commercializes eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are market-leading key commercialized vaccine products.
The Group also have 22 vaccine candidates against 13 disease areas, of which five candidates are at clinical stages. It is expected to launch at least four from 2023 to 2025. Substantially all of customers were provincial-level and county-level CDCs.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 9.71M H shares |
| No. of International Offer Shares | 8.74M H shares |
| No. of HK Offer Shares | 0.97M H shares |
| Offer Price | $16.16 |
| Stock Code | 6660 |
| Sponsor(s) | Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited, Macquarie Capital Limited |
| Underwriter(s) | Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited, Macquarie Capital Limited, BOCI Asia Limited, ICBC International Securities Limited, CMB International Capital Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Livermore Holdings Limited |
TIME TABLE
| Application Period | Sep 23 (Fri) - noon, Sep 28 (Wed) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Oct 05 (Wed) |
| Result Announcement Date | On or before Oct 05 (Wed) |
| Dealings in Shares commence on | Oct 06, 2022. (Thu) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $16.16 |
| Capitalization (H Shares) | 19.55B |
| NAV / share ($) | $2.93 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 16.16, the net proceeds raised would be HKD 70.01M, of which |
| 60% : Advance R&D of vaccine candidates and enrich vaccine pipeline |
| 35% : Construction of new production facilities |
| 5% : Expand sales and marketing team |
IPO NEWS
| 06/10/2022 16:08 |
| {New Stock}AIM VACCINE(06660) ends up 3.09% at HK$16.66 |
| 06/10/2022 09:20 |
| {New Stock}AIM VACCINE(06660) opens down 7.18% at HK$15 |
| 05/10/2022 18:35 |
| {New Stock}AIM VACCINE(06660) ends down 1.11% on grey market |
| 05/10/2022 16:20 |
| {New Stock}AIM VACCINE up 0.25% at HK$16.2 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).